

IMMUNE MODULATION & LONGEVITY

Thymosin

Alpha-1

Immune resilience



Potential benefits

- ✓ Strengthens & balances immune response
- ✓ Supports defense against infection
- ✓ Helps modulate inflammation
- ✓ Promotes long-term vitality
- ✓ Aids immune recovery & resilience

AVAILABLE AS

Injection

Thymosin Alpha-1

Thymic Immunomodulatory Peptide (Ta1) / 28 amino acid thymic peptide (TLR9 activator)

Schedule: Rx only (compounded)

Route: Subcutaneous

Dosage Form: Sterile injection

Compounding Standard: USP 797 sterile compounded

1. Medication Identification

28 amino acid thymic peptide used internationally for immune modulation. PCI Pharmacy formulation: 1.5 mg/mL sterile injection in 6 mL vials.

2. Indication / Therapeutic Use

Off-label support for immune modulation, post-infection recovery, mold toxicity protocols, autoimmune thyroid support, and chemotherapy supportive care.

3. Dosing and Administration

Dose: 1.5 mg subcutaneous per injection

Frequency: Twice weekly

Duration: Typical course 3 to 4 weeks; reassess per protocol

Timing: Per prescriber protocol

What to do if a dose is missed: Administer/Take your next dose when you remember. If within 12 hours of your next scheduled dose, skip the dose and take your next dose as scheduled. Do not double dose to compensate for a missed dose.

4. Mechanism of Action / Pharmacology

Enhances dendritic cell antigen presentation through TLR9 activation, improves CD4+/CD8+ T-cell and NK-cell activity, and calibrates adaptive immune responses without inducing non-specific autoimmune activation.

5. Contraindications

- ☐ Active uncontrolled autoimmune disease (use with caution)
- ☐ Recent organ transplant or active immunosuppression
- ☐ Pregnancy or lactation
- ☐ Known hypersensitivity to Ta1 or excipients

6. Warnings and Precautions

- ☐ Possible transient flu-like activation symptoms
- ☐ May activate immune responses; monitor in autoimmune patients
- ☐ Coordinate with prescriber if patient is on immunosuppressive therapy

7. Adverse Reactions

- ☐ Very well tolerated
- ☐ Rare brief injection site reactions
- ☐ Occasional mild flu-like activation, transient and self-limiting

8. Drug Interactions

- ☐ Immunosuppressants and biologics (may antagonize)
- ☐ Live vaccines (consult prescriber regarding timing)
- ☐ Other immunomodulators (additive immune activation)

9. Storage, Stability, and Beyond-Use Date

Visually inspect vial to ensure no precipitants, damage or cloudy liquid remains. Injectable: refrigerated at 35 – 42 degrees Fahrenheit, do not freeze, protected from light. Beyond-use date per pharmacy SOP and USP 797 guidance.

10. Compounding and Dispensing Notes

Sterile compounded injectable prepared under USP 797 conditions. Inspect for clarity. Document lot, BUD, and patient-specific Rx.